Royalty Report: Drugs, Pain, Disease – Collection: 279382

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Pain
  • Disease
  • Migraine
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 279382

License Grant
Licensor grants an exclusive license under Licensor Know-How and Licensed Patents to make, have made, use, sell, offer for sale, and import Compound and Product in the Field in theTerritory.
License Property
Licensor has certain intellectual property rights relating to its non-selective AMPA/Kainate receptor antagonist.

The patents include, but are not limited to Excitatory amino acid receptor antagonists, and, Process for preparing isoquinoline compounds, and, Synthesis of cis-decahydroisoquinoline-3-carboxylic acids.

AMPA/kainate, or AK, antagonist assets including its lead drug candidate, tezampanel, and NGX426.

Tezampanel has a range of effects which may be useful for medicinal purposes, as well as its applications in scientific research. It suppresses both the withdrawal symptoms from morphine and other opioids, and the development of tolerance,as well as having and analgesic effects in its own right. It also has anxiolytic effects in animal studies and has been suggested as a candidate for the treatment of anxiety in humans.

Field of Use
The Field means all human therapeutic indications including, but not limited to, migraine, post-operative pain and epilepsy.

IPSCIO Record ID: 203524

License Grant
Licensor grants an exclusive, except as to Licensor for internal research purposes only and not for clinical development, license under Know How, the Licensed Patents arid the Process Licensed Patents, to develop, obtain Regulatory Approval for, use, make, have made, import, sell, and offer for sale New Compounds and New Products in the Territory.
License Property
The patents, related foreign equivalents and know-how relate to peripherally selective opioid antagonists.

The New Compound shall mean a chemical entity (including salts and solvates thereof, which shall be considered the same New Compound for purposes of this Agreement) covered by any valid and unexpired claim of Licensed Patents, but shall exclude in all cases the Roberts Agreement Compound.

The New Product means a finished, formulated pharmaceutical product containing a New Compound, together with all improvements and line extensions thereon which may be included in any supplement, modification or addition to the relevant Regulatory Approval to the extent that any such improvements or line extensions contain a New Compound.

Field of Use
The Field of Use means all uses as a Peripherally Selective Opioid Receptor Antagonist, where the term Peripherally Selective Opioid Receptor Antagonist shall mean a chemical entity that has a selectivity ratio of greater than 20 upon parenteral administration as measured by the ED-50 for antagonism of analgesia in the mouse writhing test in morphine-naive mice divided by the ED-50 for precipitation of diarrhea in the morphine-dependent mice test.

Licensee is developing  alvimopan, a peripherally selective mu opioid antagonist for management of postoperative ileus, opioid induced bowel dysfunction and certain other indications.  Alvimopan is in a class of medications called peripherally acting mu-opioid receptor antagonists. It works by protecting the bowel from the constipation effects of opioid (narcotic) medications that are used to treat pain after surgery.

IPSCIO Record ID: 230815

License Grant
Licensor shall grant the Licensee of Ireland a non-exclusive license, including the right to grant sublicense, of the Licensor Intellectual Property solely in the Field and in particular to make, have made, import, use, offer for sale and sell the Products in the Territory.

Licensor shall grant a non-exclusive sublicense of Licensors interests and entitlements solely in the Field under another Agreement in the anothers Know-How and the anothers patent Rights relating to the Compounds in the Territory, with the right to grants sublicenses.

License Property
Compounds shall mean the Licensor compounds named 220,075 and 273,547, the rights to which were licensed by Licensor pursuant to the ACY Agreement.

Product 220,075 shall mean , the twice daily oral formulation(s} using the Intellectual Property and incorporating the compound 220,075 (bicifadine- analgesic) utilizing the Technologies.

Product 273,547 shall mean the once daily oral formulation using the Intellectual Property and incorporating the compound 273,547 (nonbenzodiazapinen anxiolytic) utilizing the Technologies.

Field of Use
Field shall mean the research, development and commercialization of oral Controlled Release formulations of the Products.

IP relates to a controlled release formulations of bicifadine for the treatment of pain and ocinaplon for the treatment of anxiety disorders and epilepsy.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.